News Headlines

  1. Zydus Partners With Bioeq For U.S. Commercialisation Rights For NUFYMCO®, An Interchangeable Biosimilar To Lucentis® 12/26/2025

    Bioeq AG ("Bioeq"), a Swiss biopharmaceutical company, and Zydus Lifesciences Limited ("Zydus"), an innovation-led life-sciences company with an international presence, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq, for the licensing, supply and commercialization of Bioeq`s Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO®, an interchangeable biosimilar of Lucentis®1 (Ranibizumab) for the U.S. market.

  2. Akari Therapeutics Initiates GMP Manufacturing Of AKTX-101 ADC Program To Support Phase 1 First-In-Human Clinical Trial 12/23/2025

    Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today announced the initiation of GMP manufacturing activities to support the development of AKTX-101, the Company’s lead ADC program.

  3. Samsung Biologics Expands U.S. Manufacturing Capabilities With Strategic Acquisition Of Human Genome Sciences From GSK 12/22/2025

    This strategic move secures Samsung Biologics’ first U.S.-based manufacturing site, a significant expansion of the company’s global footprint and its long-term commitment to the U.S. market.

  4. datma And Rhythm Biosciences Announce Collaboration To Apply Federated Real-World Data To Genomic Diagnostic Development 12/22/2025

    datma, a leader in federated real-world data access, and Rhythm Biosciences Ltd (ASX:RHY), a leading developer in predictive cancer diagnostics technology including its geneType™ risk assessment portfolio, today announced an exploratory collaboration to evaluate how datma.FED, datma's federated data platform, could support and accelerate the commercialization of Rhythm's genomic-integrated cancer risk prediction portfolio.

  5. Rectify And Boehringer Ingelheim Collaborate To Advance First-In-class Treatments For Chronic Kidney Disease 12/22/2025

    Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company pioneering positive functional modulators (PFMs) that restore and enhance membrane protein function, has entered a strategic research and licensing agreement with Boehringer Ingelheim to accelerate the development of treatments for chronic kidney disease (CKD) and other conditions.

  6. mAbxience And Amneal Announce FDA Approval For Denosumab Biosimilars, Referencing Prolia® And XGEVA® 12/22/2025

    mAbxience, a group of companies majority-owned by Fresenius Kabi and partly owned by Insud Pharma, and Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) announced today that the U.S. Food and Drug Administration (FDA) has approved their Biologics License Applications (BLAs) for Boncresa™ (denosumab mobz), a biosimilar based on Prolia®, and Oziltus™ (denosumab mobz), a biosimilar based on XGEVA®.

  7. Pluri And Remedy Cell Expand Collaboration; Successful Engineering Runs And Clinical-Grade Manufacturing Achieved 12/22/2025

    Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd.

  8. Mercury Bio And Meta-Flux Announce Strategic Collaboration To Advance Large-Molecule Therapeutics For Parkinson's And Alzheimer's Diseases 12/19/2025

    Mercury Bio, a biotechnology company advancing large-molecule therapeutics for neurodegenerative disease, and Meta-Flux, an AI-powered disease simulation company, have announced a strategic collaboration to accelerate the development of new therapeutic programs for central nervous system (CNS) disorders, beginning with Parkinson's disease and Alzheimer's disease.

  9. MEDIPOST Announces The Exclusive Commercialization License Agreement With Teikoku Seiyaku For Knee Osteoarthritis Treatment CARTISTEM® In Japan 12/19/2025

    MEDIPOST Co., Ltd. (KOSDAQ 078160), a fully integrated cell therapy biotechnology company, today announced a multi-year partnership with Japan's Teikoku Seiyaku Co., Ltd. for the commercialization of CARTISTEM®, an innovative treatment for knee osteoarthritis, in the Japanese market.

  10. Zydus And Formycon Enter Into An Exclusive Partnership For The Licensing And Supply Of Biosimilar To Keytruda® (Pembrolizumab), In US And Canada 12/19/2025

    Zydus Lifesciences Limited (including its subsidiaries and affiliates), an innovation-led life-sciences company, with an international presence, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Formycon AG for the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda®1 (Pembrolizumab) in the USA and Canada market.